Arcellx won the battle of BCMA CAR-T therapies

This story first appeared in Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox.

I just returned from San Diego and the annual meeting of the American Society of Hematology, where Arcellx won the battle of BCMA CAR-T therapies against Legend Biotech.

Legend has downplayed the significance of the 12-17% rate of delayed neurotoxicity — Parkinsonian symptoms and cranial nerve palsies — reported in multiple myeloma patients receiving its therapy, called Carvykti. Chief executive Ying Huang, speaking to investors and analysts at a company meeting, insisted it’s a receding issue, especially now that Carvykti is establishing a role in treating patients with less advanced disease.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$20

for 3 months, then $399/year

$20 for 3 months Get Started

Then $399/year

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe

Log In